Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The drug, called CPI-006, targets an immune signaling molecule called CD73 and activates CD73POS B cells, which subsequently promotes antibody production and differentiation into B cells.

In vitro, CPI-006 induces markers of B cell activation, maturation, antigen presentation, and transformation into antibody-secreting plasmablasts.

In a Phase 1 trial testing the safety and immunogenicity of CPI-006 among COVID-19 patients with mild to moderate disease, a single dose of the agent-induced antiviral antibody responses just 7 days following treatment, with antibody titers continuing to increase past day 56.
for more:https://ouo.io/qkuFuX